CLEO DIAGNOSTICS LTD - Announcements

3.85%

37.5¢

Market Cap $30.6M

Healthcare Medical Care

Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal... Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. It focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is absent in non-malignant disease. It is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. Triage Test is a pre-surgical test to determine ovarian or adnexal mass for which surgical referral is required who have not yet been referred to an oncologist.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

COV	Notice Required Under ASX Listing Rule 3.13.1		05/09/25	310.58KB	Share
COV	Appendix 4G and Corporate Governance Statement		26/08/25	437.28KB	Share
COV	Appendix 4E and 2025 Annual Report	PRICE SENSITIVE	26/08/25	1.22MB	Share
COV	COV Commences Health Economic Study-Support US Market Entry	PRICE SENSITIVE	18/08/25	440.71KB	Share
COV	Restricted securities to be released from escrow		15/08/25	328.83KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	21/07/25	740.81KB	Share
COV	CLEO Strengthens FDA Submission - Access to US Biobank	PRICE SENSITIVE	25/06/25	545.31KB	Share
COV	Investor Webinar		18/06/25	396.94KB	Share
COV	Corporate Presentation	PRICE SENSITIVE	12/06/25	2.56MB	Share
COV	Cleo Advances with Completion of Alpha Testing	PRICE SENSITIVE	12/05/25	526.49KB	Share
COV	CLEO to Fast Track Development of Ovarian Cancer Test	PRICE SENSITIVE	28/04/25	522.41KB	Share
COV	Notification regarding unquoted securities - COV		24/04/25	20.62KB	Share
COV	CLEO Receives A$845k Research and Development Tax Incentive	PRICE SENSITIVE	24/04/25	473.54KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	11/04/25	751.94KB	Share
COV	CLEO Delivers Commercial Development Milestone	PRICE SENSITIVE	18/03/25	511.71KB	Share
COV	Appendix 4D and Half Yearly Accounts	PRICE SENSITIVE	27/02/25	596.53KB	Share
COV	Clarification to ASX Price Query		17/02/25	461.92KB	Share
COV	Price Query Response	PRICE SENSITIVE	07/02/25	889.55KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	31/01/25	812.43KB	Share
COV	CLEO Further Expands Ovarian Cancer Trial with Siles Health	PRICE SENSITIVE	10/12/24	2.71MB	Share
COV	Results of Annual General Meeting		27/11/24	367.57KB	Share
COV	The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial	PRICE SENSITIVE	27/11/24	2.79MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	16/10/24	711.6KB	Share
COV	Letter to Shareholders		04/10/24	2.18MB	Share
COV	Notice of Annual General Meeting/Proxy Form		04/10/24	731.29KB	Share
COV	Notice Required Under ASX Listing Rule 3.13.1		23/09/24	310.63KB	Share
COV	Cleo Commences U.S. Clinical Trials	PRICE SENSITIVE	06/09/24	526.04KB	Share
COV	ASX Listing Rule 4.10.19		28/08/24	348.64KB	Share
COV	Appendix 4G and Corporate Governance Statement		27/08/24	445.04KB	Share
COV	Appendix 4E and 2024 Annual Report	PRICE SENSITIVE	27/08/24	6.18MB	Share
COV	Change of Registry Address		07/08/24	355.59KB	Share
COV	CLEO Selects U.S. Clinical Trial Sites	PRICE SENSITIVE	31/07/24	2.76MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	24/07/24	732.66KB	Share
COV	Cleo Commences US Regulatory Process with FDA	PRICE SENSITIVE	26/06/24	2.75MB	Share
COV	Application for quotation of securities - COV		24/06/24	14.19KB	Share
COV	Restricted securities to be released from escrow		14/06/24	329.6KB	Share
COV	COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark	PRICE SENSITIVE	29/05/24	2.8MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	29/04/24	4.39MB	Share
COV	COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials	PRICE SENSITIVE	11/04/24	2.78MB	Share
COV	CLEO Appoints Partner to Commence U.S. Market Access Program	PRICE SENSITIVE	02/04/24	2.79MB	Share
COV	Peer-Review Supports CLEOs Ovarian Cancer Detection Tech	PRICE SENSITIVE	25/03/24	2.79MB	Share
COV	Appendix 4D and Half Yearly Accounts	PRICE SENSITIVE	29/02/24	747.87KB	Share
COV	Corporate Presentation February 2024		20/02/24	2.32MB	Share
COV	Cleo Completes Design Transfer	PRICE SENSITIVE	12/02/24	2.7MB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	31/01/24	996.59KB	Share
COV	Results of Annual General Meeting		22/11/23	400.96KB	Share
COV	Application for quotation of securities - COV		06/11/23	28.3KB	Share
COV	Completion of First Triage Test Clinical Validation Study	PRICE SENSITIVE	06/11/23	2.96MB	Share
COV	Trading Halt	PRICE SENSITIVE	03/11/23	714.91KB	Share
COV	Pause in Trading	PRICE SENSITIVE	03/11/23	115.61KB	Share
COV	Quarterly activities and cashflow report	PRICE SENSITIVE	30/10/23	4.67MB	Share
COV	Restricted securities to be released from escrow		27/10/23	331.54KB	Share
COV	Application for quotation of securities - COV		13/10/23	30.46KB	Share
COV	Cleo Delivers Early Progress on Development Program	PRICE SENSITIVE	09/10/23	3.17MB	Share
COV	Restricted securities to be released from escrow		06/10/23	331.89KB	Share
COV	Letter to Shareholders		05/10/23	307.45KB	Share
COV	Notice of Annual General Meeting/Proxy Form		05/10/23	515.34KB	Share
COV	Cleo Enhances Board Capacity		02/10/23	2.68MB	Share
COV	Appendix 4G and Corporate Governance Statement		27/09/23	445.92KB	Share
COV	Annual Report to shareholders		27/09/23	1.54MB	Share
COV	Notice Required Under ASX Listing Rule 3.13.1		22/09/23	310.07KB	Share
COV	Change of Registry Address		21/09/23	321.78KB	Share
COV	Application for quotation of securities - COV		19/09/23	30.19KB	Share
COV	Restricted securities to be released from escrow		12/09/23	352.09KB	Share
COV	Letter from the CEO to Shareholders		01/09/23	2.74MB	Share
COV	Appendix 4E and Preliminary Financial Report	PRICE SENSITIVE	31/08/23	694.36KB	Share
COV	CLEO Granted U.S. Patent for Novel Ovarian Cancer Biomarker		22/08/23	435.58KB	Share
COV	Initial Directors Interest Notices x 5		21/08/23	244.88KB	Share
COV	Notice of initial substantial holders x 3		21/08/23	797.37KB	Share
COV	Pre-Quotation Notice		18/08/23	398.21KB	Share
COV	Distribution Schedule		18/08/23	51.75KB	Share
COV	Top 20 Holders		18/08/23	63.74KB	Share
COV	Securities Trading Policy		18/08/23	176.54KB	Share
COV	Employee Securities Incentive Plan		18/08/23	511.56KB	Share
COV	Interim Report 31 December 2022		18/08/23	741.87KB	Share
COV	Annual Report 30 June 2022		18/08/23	752.4KB	Share
COV	Constitution		18/08/23	451.66KB	Share
COV	Replacement Prospectus		18/08/23	3.29MB	Share
COV	Information Form and Checklist		18/08/23	343.81KB	Share
COV	Appendix 1A		18/08/23	59.51KB	Share
COV	ASX Notice - Admission and Quotation		18/08/23	442.54KB	Share
COV	Removal from Official List (cob 24 02 2010)		23/02/10	30.46KB	Share
COV +TGF	Amended ASX Circular - Scheme of Arrangement		12/02/10	48.22KB	Share
COV	Suspension from official quotation	PRICE SENSITIVE	11/02/10	30.71KB	Share
COV +TGF	Court Order Lodged with ASIC		10/02/10	117.27KB	Share
COV +TGF	Federal Court Approves Scheme		09/02/10	120.4KB	Share
COV +TGF	ASX Circular - Scheme of Arrangement		08/02/10	48.19KB	Share
COV +TGF	Results of General Meeting to Approve Scheme		28/01/10	126.92KB	Share
COV	Quarterly Report and Appendix 5B	PRICE SENSITIVE	25/01/10	2.51MB	Share
COV +TGF	Scheme Booklet and Notice of Scheme Meeting		24/12/09	15.92MB	Share
COV +TGF	Update on Merger with Tianshan Goldfields Limited		22/12/09	137.97KB	Share
COV +TGF	Corvette Issues Second Convertible Note		18/12/09	89.6KB	Share
COV +TGF	Corvette Issues Second Convertible Note	PRICE SENSITIVE	18/12/09	67.46KB	Share
COV	Presentation to Gold Investor Forum, Sydney, 7 Dec 09		07/12/09	3.05MB	Share
COV +TGF	$60M Merger Agreement Executed		27/11/09	97.38KB	Share
COV +TGF	Tianshan and Corvette sign Merger Implementation Agreement		27/11/09	136.37KB	Share
COV	Results of Annual General Meeting		26/11/09	143.67KB	Share
COV	AGM Presentation		24/11/09	2.18MB	Share
COV	Appendix 3B - Issue of Options		20/11/09	66.94KB	Share
COV	Merger Agreement		17/11/09	94.13KB	Share

COV Notice Required Under ASX Listing Rule 3.13.1
05/09/25		310.58KB	Share
COV Appendix 4G and Corporate Governance Statement
26/08/25		437.28KB	Share
COV Appendix 4E and 2025 Annual Report
26/08/25	PRICE SENSITIVE	1.22MB	Share
COV COV Commences Health Economic Study-Support US Market Entry
18/08/25	PRICE SENSITIVE	440.71KB	Share
COV Restricted securities to be released from escrow
15/08/25		328.83KB	Share
COV Quarterly activities and cashflow report
21/07/25	PRICE SENSITIVE	740.81KB	Share
COV CLEO Strengthens FDA Submission - Access to US Biobank
25/06/25	PRICE SENSITIVE	545.31KB	Share
COV Investor Webinar
18/06/25		396.94KB	Share
COV Corporate Presentation
12/06/25	PRICE SENSITIVE	2.56MB	Share
COV Cleo Advances with Completion of Alpha Testing
12/05/25	PRICE SENSITIVE	526.49KB	Share
COV CLEO to Fast Track Development of Ovarian Cancer Test
28/04/25	PRICE SENSITIVE	522.41KB	Share
COV Notification regarding unquoted securities - COV
24/04/25		20.62KB	Share
COV CLEO Receives A$845k Research and Development Tax Incentive
24/04/25	PRICE SENSITIVE	473.54KB	Share
COV Quarterly activities and cashflow report
11/04/25	PRICE SENSITIVE	751.94KB	Share
COV CLEO Delivers Commercial Development Milestone
18/03/25	PRICE SENSITIVE	511.71KB	Share
COV Appendix 4D and Half Yearly Accounts
27/02/25	PRICE SENSITIVE	596.53KB	Share
COV Clarification to ASX Price Query
17/02/25		461.92KB	Share
COV Price Query Response
07/02/25	PRICE SENSITIVE	889.55KB	Share
COV Quarterly activities and cashflow report
31/01/25	PRICE SENSITIVE	812.43KB	Share
COV CLEO Further Expands Ovarian Cancer Trial with Siles Health
10/12/24	PRICE SENSITIVE	2.71MB	Share
COV Results of Annual General Meeting
27/11/24		367.57KB	Share
COV The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
27/11/24	PRICE SENSITIVE	2.79MB	Share
COV Quarterly activities and cashflow report
16/10/24	PRICE SENSITIVE	711.6KB	Share
COV Letter to Shareholders
04/10/24		2.18MB	Share
COV Notice of Annual General Meeting/Proxy Form
04/10/24		731.29KB	Share
COV Notice Required Under ASX Listing Rule 3.13.1
23/09/24		310.63KB	Share
COV Cleo Commences U.S. Clinical Trials
06/09/24	PRICE SENSITIVE	526.04KB	Share
COV ASX Listing Rule 4.10.19
28/08/24		348.64KB	Share
COV Appendix 4G and Corporate Governance Statement
27/08/24		445.04KB	Share
COV Appendix 4E and 2024 Annual Report
27/08/24	PRICE SENSITIVE	6.18MB	Share
COV Change of Registry Address
07/08/24		355.59KB	Share
COV CLEO Selects U.S. Clinical Trial Sites
31/07/24	PRICE SENSITIVE	2.76MB	Share
COV Quarterly activities and cashflow report
24/07/24	PRICE SENSITIVE	732.66KB	Share
COV Cleo Commences US Regulatory Process with FDA
26/06/24	PRICE SENSITIVE	2.75MB	Share
COV Application for quotation of securities - COV
24/06/24		14.19KB	Share
COV Restricted securities to be released from escrow
14/06/24		329.6KB	Share
COV COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
29/05/24	PRICE SENSITIVE	2.8MB	Share
COV Quarterly activities and cashflow report
29/04/24	PRICE SENSITIVE	4.39MB	Share
COV COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
11/04/24	PRICE SENSITIVE	2.78MB	Share
COV CLEO Appoints Partner to Commence U.S. Market Access Program
02/04/24	PRICE SENSITIVE	2.79MB	Share
COV Peer-Review Supports CLEOs Ovarian Cancer Detection Tech
25/03/24	PRICE SENSITIVE	2.79MB	Share
COV Appendix 4D and Half Yearly Accounts
29/02/24	PRICE SENSITIVE	747.87KB	Share
COV Corporate Presentation February 2024
20/02/24		2.32MB	Share
COV Cleo Completes Design Transfer
12/02/24	PRICE SENSITIVE	2.7MB	Share
COV Quarterly activities and cashflow report
31/01/24	PRICE SENSITIVE	996.59KB	Share
COV Results of Annual General Meeting
22/11/23		400.96KB	Share
COV Application for quotation of securities - COV
06/11/23		28.3KB	Share
COV Completion of First Triage Test Clinical Validation Study
06/11/23	PRICE SENSITIVE	2.96MB	Share
COV Trading Halt
03/11/23	PRICE SENSITIVE	714.91KB	Share
COV Pause in Trading
03/11/23	PRICE SENSITIVE	115.61KB	Share
COV Quarterly activities and cashflow report
30/10/23	PRICE SENSITIVE	4.67MB	Share
COV Restricted securities to be released from escrow
27/10/23		331.54KB	Share
COV Application for quotation of securities - COV
13/10/23		30.46KB	Share
COV Cleo Delivers Early Progress on Development Program
09/10/23	PRICE SENSITIVE	3.17MB	Share
COV Restricted securities to be released from escrow
06/10/23		331.89KB	Share
COV Letter to Shareholders
05/10/23		307.45KB	Share
COV Notice of Annual General Meeting/Proxy Form
05/10/23		515.34KB	Share
COV Cleo Enhances Board Capacity
02/10/23		2.68MB	Share
COV Appendix 4G and Corporate Governance Statement
27/09/23		445.92KB	Share
COV Annual Report to shareholders
27/09/23		1.54MB	Share
COV Notice Required Under ASX Listing Rule 3.13.1
22/09/23		310.07KB	Share
COV Change of Registry Address
21/09/23		321.78KB	Share
COV Application for quotation of securities - COV
19/09/23		30.19KB	Share
COV Restricted securities to be released from escrow
12/09/23		352.09KB	Share
COV Letter from the CEO to Shareholders
01/09/23		2.74MB	Share
COV Appendix 4E and Preliminary Financial Report
31/08/23	PRICE SENSITIVE	694.36KB	Share
COV CLEO Granted U.S. Patent for Novel Ovarian Cancer Biomarker
22/08/23		435.58KB	Share
COV Initial Directors Interest Notices x 5
21/08/23		244.88KB	Share
COV Notice of initial substantial holders x 3
21/08/23		797.37KB	Share
COV Pre-Quotation Notice
18/08/23		398.21KB	Share
COV Distribution Schedule
18/08/23		51.75KB	Share
COV Top 20 Holders
18/08/23		63.74KB	Share
COV Securities Trading Policy
18/08/23		176.54KB	Share
COV Employee Securities Incentive Plan
18/08/23		511.56KB	Share
COV Interim Report 31 December 2022
18/08/23		741.87KB	Share
COV Annual Report 30 June 2022
18/08/23		752.4KB	Share
COV Constitution
18/08/23		451.66KB	Share
COV Replacement Prospectus
18/08/23		3.29MB	Share
COV Information Form and Checklist
18/08/23		343.81KB	Share
COV Appendix 1A
18/08/23		59.51KB	Share
COV ASX Notice - Admission and Quotation
18/08/23		442.54KB	Share
COVRemoval from Official List (cob 24 02 2010)
23/02/10		30.46KB	Share
COV +TGFAmended ASX Circular - Scheme of Arrangement
12/02/10		48.22KB	Share
COVSuspension from official quotation
11/02/10	PRICE SENSITIVE	30.71KB	Share
COV +TGFCourt Order Lodged with ASIC
10/02/10		117.27KB	Share
COV +TGFFederal Court Approves Scheme
09/02/10		120.4KB	Share
COV +TGFASX Circular - Scheme of Arrangement
08/02/10		48.19KB	Share
COV +TGFResults of General Meeting to Approve Scheme
28/01/10		126.92KB	Share
COVQuarterly Report and Appendix 5B
25/01/10	PRICE SENSITIVE	2.51MB	Share
COV +TGFScheme Booklet and Notice of Scheme Meeting
24/12/09		15.92MB	Share
COV +TGFUpdate on Merger with Tianshan Goldfields Limited
22/12/09		137.97KB	Share
COV +TGFCorvette Issues Second Convertible Note
18/12/09		89.6KB	Share
COV +TGFCorvette Issues Second Convertible Note
18/12/09	PRICE SENSITIVE	67.46KB	Share
COVPresentation to Gold Investor Forum, Sydney, 7 Dec 09
07/12/09		3.05MB	Share
COV +TGF$60M Merger Agreement Executed
27/11/09		97.38KB	Share
COV +TGFTianshan and Corvette sign Merger Implementation Agreement
27/11/09		136.37KB	Share
COVResults of Annual General Meeting
26/11/09		143.67KB	Share
COVAGM Presentation
24/11/09		2.18MB	Share
COVAppendix 3B - Issue of Options
20/11/09		66.94KB	Share
COVMerger Agreement
17/11/09		94.13KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 37.5¢		Change -0.015(3.85%)		Mkt cap ! $30.6M

Open	High	Low	Value	Volume
39.0¢	39.0¢	37.5¢	$57.09K	150.4K

Buyers (Bids)

No.	Vol.	Price($)
3	28671	37.5¢

Sellers (Offers)

Price($)	Vol.	No.
38.0¢	25000	1

View Market Depth

No.	Vol.	Price($)
3	28671	0.375
2	102972	0.370
3	13575	0.350
2	22767	0.345
6	83767	0.340

Price($)	Vol.	No.
0.380	25000	1
0.390	8832	1
0.395	73910	1
0.400	9271	1
0.410	15919	2

Last trade - 16.10pm 12/09/2025 (20 minute delay)

COV (ASX) Chart

CLEO DIAGNOSTICS LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available